Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 31;12(3):406–424. doi: 10.21037/tau-23-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2023 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The mutation classifier as opposed to TMB as an independent prognostic factor for ICI therapy in patients with advanced RCC. (A,B) Univariate and multivariate Cox regression analyses of OS were performed in the CheckMate ICI therapy cohort. (C) The distribution of the risk scores and OS status in the CheckMate ICI therapy cohort. (D) Kaplan-Meier curves show the difference in OS between the low- and high-risk groups in the CheckMate ICI therapy cohort. (E) Kaplan-Meier curves of OS in the CheckMate ICI therapy cohort according to TMB. (F,G) Kaplan-Meier curves of OS in patients from the high- and low-TMB groups in the CheckMate ICI therapy cohort. TMB, tumoral mutation burden; RCC, renal cell carcinoma; ICI, immune checkpoint inhibitor; HR, hazard ratio; OS, overall survival.